ANXA1 and granular corneal dystrophy type II: Furthermore, this is the first research in which both spinal (intrathecal) and systemic (intravenous) therapies with ANXA1-derived peptide Ac2-26 have been found to prevent and attenuate persistent itch-like scratching behaviors following ACD and cholestasis.